Neurokinin-1 receptor antagonist aprepitant regulates autophagy and apoptosis via ROS/JNK in intrahepatic
Yang Yang1, Xueyan Cao1, Yuting Wang1
1Institute of Digestive Endoscopy and Medical Center for Digestive Diseases, Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Background:
Intrahepatic cholangiocarcinoma (iCCA) has a poor prognosis and limited treatment options. Aprepitant, a selective NK-1R antagonist, can inhibit the growth of various tumours in vitro and in vivo. However, it remains unclear whether aprepitant has cytotoxic effects on iCCA.
Methods:
We measured the expression of SP/NK-1R in clinical samples of iCCA by immunohistochemistry. Then, we detected the cytotoxic effects of aprepitant on iCCA cells via MTT, EdU and colony formation assay. We constructed a subcutaneous xenograft model of BALB/c nude mice by using HCCC-9810 and RBE cell lines to explore the effects of aprepitant in vivo. To elucidate the potential mechanisms, we explored the pro-apoptotic effect of aprepitant by flow cytometric, western blotting, ROS detection and JC-1 staining. Furthermore, we detected the autophagic level of HCCC-9810 and RBE by western blotting, mRFP-eGFP-LC3 adenovirus transfection and electron microscope.
Results:
SP/NK-1R is significantly expressed in iCCA. Aprepitant inhibited human iCCA xenograft growth and dose-dependently decreased the viability of RBE and HCCC-9810 cells. Aprepitant-induced mitochondria-dependent apoptosis through ROS/JNK pathway. Additionally, pretreatment with z-VAD-fmk partly reversed the effect of aprepitant on cell viability, while NAC completely attenuated the cytotoxic effects of aprepitant in vitro. Furthermore, we observed the dynamic changes of autophagosome in RBE and HCCC-9810 cells treated with aprepitant.
Conclusion:
SP/NK-1R signalling is significantly activated in iCCA and promotes the proliferation of iCCA cells. By contrast, aprepitant can induce autophagy and apoptosis in iCCA cells via ROS accumulation and subsequent activation of JNK.
Insights
Aprepitant shows cytotoxic effects on intrahepatic cholangiocarcinoma (iCCA) by inducing apoptosis and autophagy. This study investigates aprepitant
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Intrahepatic cholangiocarcinoma (iCCA) presents a poor prognosis with limited therapeutic strategies.
- Aprepitant, a neurokinin-1 receptor (NK-1R) antagonist, exhibits anti-tumorigenic properties in various cancer models.
- The potential of aprepitant in treating iCCA remains largely unexplored.
Purpose of the Study:
- To investigate the expression of Substance P/NK-1R (SP/NK-1R) in iCCA.
- To evaluate the cytotoxic effects of aprepitant on iCCA cells in vitro and in vivo.
- To elucidate the underlying molecular mechanisms of aprepitant's action in iCCA.
Main Methods:
- Immunohistochemistry was used to assess SP/NK-1R expression in clinical iCCA samples.
- In vitro cytotoxicity was evaluated using MTT, EdU, and colony formation assays on iCCA cell lines (HCCC-9810, RBE).
- In vivo efficacy was assessed using a subcutaneous xenograft mouse model, with mechanistic studies involving flow cytometry, western blotting, ROS detection, and JC-1 staining.
Main Results:
- SP/NK-1R was significantly expressed in iCCA tissues.
- Aprepitant demonstrated dose-dependent inhibition of iCCA cell viability and xenograft growth.
- Aprepitant induced mitochondria-dependent apoptosis via the ROS/JNK pathway and triggered dynamic autophagosome changes.
Conclusions:
- SP/NK-1R signaling is activated in iCCA and contributes to tumor proliferation.
- Aprepitant effectively inhibits iCCA growth by inducing apoptosis and autophagy.
- The mechanism involves ROS accumulation and subsequent JNK pathway activation.
More Related Videos
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Apoptosis


